Medicare AdvantageCoverageLow impact
MA08.036g, Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ), Cipaglucosidase alfa-atga (Pombiliti™ )
Independence Blue Cross·Genetics, Internal Medicine, Pediatrics·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
This is a reissued Medicare Advantage pharmacy policy (MA08.036g) effective April 1, 2026, covering three enzyme replacement therapies for Pompe disease: Alglucosidase alfa (Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme®), and Cipaglucosidase alfa-atga (Pombiliti™). The billing team must verify coverage requirements, prior authorization rules, and any changes to reimbursement or documentation for these specialty medications.
Action Required
By March 15, 2026: Billing team must obtain and review the full MA08.036g policy text from the provided source URL to identify specific prior authorization requirements, covered dosing/frequency, and documentation standards for Lumizyme®, Nexviazyme®, and Pombiliti™. Update authorization workflows and provider alerts accordingly. Communicate any changes to providers treating rare genetic/metabolic disease patients. Confirm reimbursement rates and billing codes (likely HCPCS J-codes for these biologics) in billing system before the April 1, 2026 effective date to prevent claim delays or denials.